Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 2/20 | 0.52 |
| ▸ | CTSK | P43235 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 2/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | MMP3 | P08254 | 1/20 | 0.49 |
| ▸ | MMP7 | P09237 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | MME | P08473 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.44 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11352345 | 0.95 | FPR2 (0.59) | FPR2CTSKMMP2MMP1MMP3 | |
| SCHEMBL839119 | 0.85 | FPR2 (0.55) | FPR2CTSKMMP2MMP1MMP3 | |
| SCHEMBL18614301 | 0.85 | FPR2 (0.55) | FPR2CTSKMMP2MMP1MMP3 | |
| SCHEMBL148423 | 0.84 | FOLH1 (0.55) | MMEL3MBTL1FOLH1ALDH1A1 | |
| SCHEMBL8414223 | 0.84 | FOLH1 (0.55) | MMEL3MBTL1FOLH1ALDH1A1 | |
| SCHEMBL11581853 | 0.84 | MME (0.56) | MMP2MMP9MMEFOLH1ALDH1A1 | |
| SCHEMBL73955 | 0.84 | MME (0.56) | MMP2MMP9MMEFOLH1ALDH1A1 | |
| SCHEMBL497336 | 0.84 | MME (0.56) | MMP2MMP9MMEFOLH1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1681289 | 0.83 | FPR2 (0.54) | FPR2CTSKMMP2MMP1MMP3 | |
| SCHEMBL1097658 | 0.83 | FPR2 (0.52) | FPR2MMEFOLH1ALDH1A1MEP1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153365-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2012-04-10 | — | — | US | disclosed |
| US-8034909-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2011-10-11 | — | — | US | disclosed |
| US-20110245327-A1 | Oligonucleotide Analogues | EXIQON A/S (DK) | 2011-10-06 | — | — | US | disclosed |
| EP-2341057-A2 | Oligonucleotide Analogues | Exiqon A/S (DK) | 2011-07-06 | — | — | EP | disclosed |
| EP-2341058-A2 | Oligonucleotide Analogues | Exiqon A/S (DK) | 2011-07-06 | — | — | EP | disclosed |
| US-20080227847-A1 | Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use | ADITECH PHARMA AB (SE) | 2008-09-18 | — | — | US | disclosed |
| US-6376655-B1 | APPLYING EXTERNAL STIMULATION; OPTICAL ANISOTROPY | RISO NATIONAL LABORATORY (DK) | 2002-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245327-A1 | Oligonucleotide Analogues | POLRMT, POLM, POLN | FPR2 3091/4885CTSK 3244/4885MMP2 3842/4885 |
| US-20080227847-A1 | Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use | FAH, SLC16A1, FH | FPR2 347/4885CTSK 2115/4885MMP2 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.